Clarkston Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-46,815
| Closed | -$2.53M | – | 112 |
|
|
2025
Q4 | $2.53M | Buy |
46,815
+815
| +2% | +$39.2K | 0.06% | 93 |
|
|
2025
Q3 | $2.07M | Hold |
46,000
| – | – | 0.04% | 93 |
|
|
2025
Q2 | $2.13M | Hold |
46,000
| – | – | 0.05% | 86 |
|
|
2025
Q1 | $2.81M | Hold |
46,000
| – | – | 0.06% | 73 |
|
|
2024
Q4 | $2.6M | Hold |
46,000
| – | – | 0.05% | 73 |
|
|
2024
Q3 | $2.38M | Buy |
46,000
+5,000
| +12% | +$235K | 0.04% | 71 |
|
|
2024
Q2 | $1.7M | Hold |
41,000
| – | – | 0.03% | 82 |
|
|
2024
Q1 | $2.22M | Hold |
41,000
| – | – | 0.04% | 73 |
|
|
2023
Q4 | $2.1M | Hold |
41,000
| – | – | 0.04% | 69 |
|
|
2023
Q3 | $2.38M | Hold |
41,000
| – | – | 0.05% | 67 |
|
|
2023
Q2 | $2.62M | Hold |
41,000
| – | – | 0.05% | 64 |
|
|
2023
Q1 | $2.84M | Hold |
41,000
| – | – | 0.05% | 60 |
|
|
2022
Q4 | $2.95M | Hold |
41,000
| – | – | 0.06% | 58 |
|
|
2022
Q3 | $2.92M | Hold |
41,000
| – | – | 0.06% | 56 |
|
|
2022
Q2 | $3.16M | Hold |
41,000
| – | – | 0.06% | 55 |
|
|
2022
Q1 | $2.99M | Sell |
41,000
-16
| -0% | -$1.07K | 0.05% | 58 |
|
|
2021
Q4 | $2.56M | Buy |
+41,016
| New | +$2.41M | 0.04% | 61 |
|
|
2017
Q1 | – | Sell |
-34,600
| Closed | -$2.02M | – | 100 |
|
|
2016
Q4 | $2.02M | Sell |
34,600
-2,500
| -7% | -$137K | 0.1% | 57 |
|
|
2016
Q3 | $2M | Buy |
37,100
+2,500
| +7% | +$161K | 0.1% | 58 |
|
|
2016
Q2 | $2.54M | Sell |
34,600
-500
| -1% | -$35.3K | 0.13% | 58 |
|
|
2016
Q1 | $2.24M | Sell |
35,100
-2,007
| -5% | -$127K | 0.12% | 60 |
|
|
2015
Q4 | $2.55M | Sell |
37,107
-1,250
| -3% | -$82.6K | 0.18% | 59 |
|
|
2015
Q3 | $2.27M | Sell |
38,357
-100
| -0.3% | -$6.34K | 0.21% | 61 |
|
|
2015
Q2 | $2.56M | Sell |
38,457
-350
| -0.9% | -$23.1K | 0.26% | 63 |
|
|
2015
Q1 | $2.5M | Sell |
38,807
-6,151
| -14% | -$385K | 0.28% | 65 |
|
|
2014
Q4 | $2.65M | Sell |
44,958
-325
| -0.7% | -$18.3K | 0.4% | 61 |
|
|
2014
Q3 | $2.32M | Sell |
45,283
-450
| -1% | -$22.5K | 0.4% | 63 |
|
|
2014
Q2 | $2.22M | Sell |
45,733
-2,150
| -4% | -$106K | 0.41% | 61 |
|
|
2014
Q1 | $2.49M | Buy |
47,883
+39,641
| +481% | +$2.11M | 0.5% | 55 |
|
|
2013
Q4 | $438K | Buy |
8,242
+2,692
| +49% | +$137K | 0.17% | 75 |
|
|
2013
Q3 | $257K | Sell |
5,550
-2,500
| -31% | -$110K | 0.12% | 86 |
|
|
2013
Q2 | $360K | Buy |
+8,050
| New | +$349K | 0.2% | 76 |
|
Other funds holding BMY
VCM
VPM
Clarkston Capital Partners's BMY Position: Q1 2026 in Review
Clarkston Capital Partners sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 46,815 shares — an estimated $2.53M sold.
Clarkston Capital Partners first reported a position in BMY in Q2 2013 and held it in 32 quarters. The position peaked at $3.16M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Clarkston Capital Partners reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- Clarkston Capital Partners sold 46,815 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.53M.
- Clarkston Capital Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 32 quarters.
- Clarkston Capital Partners's Bristol-Myers Squibb position peaked at $3.16M in Q2 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Clarkston Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.